NOVATARG, INC. — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): There are approximately 12 million people suffering f
NOVATARG, INC. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $415,078
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-088
- NAICS
- —
- Place of performance
- NC
- Period
- —
Description
DESCRIPTION (provided by applicant): There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of gt 2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKDpatients. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of gt 2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.